BetterLife Pharma Inc. (BETR.CN)
CAD 0.11
(0.0%)
CAD 0.11
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.24 Million CAD | 65.75% |
| 2022 | -9.46 Million CAD | 7.32% |
| 2021 | -10.2 Million CAD | -28.96% |
| 2020 | -7.91 Million CAD | 57.74% |
| 2019 | -18.73 Million CAD | -178.34% |
| 2018 | -6.72 Million CAD | -419.87% |
| 2017 | -1.29 Million CAD | 83.6% |
| 2016 | -7.89 Million CAD | 34.28% |
| 2015 | -12.01 Million CAD | -9081.83% |
| 2014 | -130.81 Thousand CAD | -70.13% |
| 2013 | -76.88 Thousand CAD | 13.51% |
| 2012 | -88.89 Thousand CAD | 75.48% |
| 2011 | -362.51 Thousand CAD | -151.16% |
| 2010 | -144.33 Thousand CAD | -21.33% |
| 2009 | -118.96 Thousand CAD | 81.79% |
| 2008 | -653.23 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.26 Million CAD | -210.48% |
| 2024 Q2 | -1.16 Million CAD | 48.45% |
| 2023 Q3 | -856.47 Thousand CAD | 7.61% |
| 2023 Q2 | -926.97 Thousand CAD | -10.76% |
| 2023 Q1 | -836.9 Thousand CAD | -32.71% |
| 2023 Q4 | -730.25 Thousand CAD | 14.74% |
| 2023 FY | -3.2 Million CAD | 66.07% |
| 2022 Q4 | -630.62 Thousand CAD | 86.12% |
| 2022 Q1 | -3.05 Million CAD | -35.37% |
| 2022 Q2 | -1.23 Million CAD | 59.66% |
| 2022 Q3 | -4.54 Million CAD | -268.98% |
| 2022 FY | -9.46 Million CAD | 7.32% |
| 2021 Q2 | -3.35 Million CAD | -36.65% |
| 2021 FY | -10.2 Million CAD | -28.96% |
| 2021 Q1 | -2.45 Million CAD | -10.29% |
| 2021 Q3 | -2.14 Million CAD | 36.16% |
| 2021 Q4 | -2.25 Million CAD | -5.3% |
| 2020 Q2 | -1.56 Million CAD | -41.73% |
| 2020 Q1 | -1.1 Million CAD | 89.47% |
| 2020 Q4 | -2.22 Million CAD | 22.82% |
| 2020 FY | -7.91 Million CAD | 57.74% |
| 2020 Q3 | -2.88 Million CAD | -84.52% |
| 2019 FY | -18.73 Million CAD | -178.34% |
| 2019 Q1 | -1.66 Million CAD | -7.54% |
| 2019 Q4 | -10.47 Million CAD | -348.71% |
| 2019 Q3 | -2.33 Million CAD | 45.11% |
| 2019 Q2 | -4.25 Million CAD | -155.98% |
| 2018 Q2 | -1.53 Million CAD | 17.17% |
| 2018 Q1 | -1.85 Million CAD | -399.22% |
| 2018 Q4 | -1.54 Million CAD | 16.61% |
| 2018 Q3 | -1.85 Million CAD | -20.37% |
| 2018 FY | -6.72 Million CAD | -419.87% |
| 2017 Q1 | -389.6 Thousand CAD | 57.44% |
| 2017 FY | -1.29 Million CAD | 83.6% |
| 2017 Q4 | -372.16 Thousand CAD | -57.1% |
| 2017 Q3 | -236.89 Thousand CAD | 23.59% |
| 2017 Q2 | -310.03 Thousand CAD | 20.42% |
| 2016 Q2 | -1.54 Million CAD | 63.17% |
| 2016 Q3 | -926.08 Thousand CAD | 39.89% |
| 2016 FY | -7.89 Million CAD | 34.28% |
| 2016 Q4 | -915.49 Thousand CAD | 1.14% |
| 2016 Q1 | -4.18 Million CAD | 45.03% |
| 2015 Q4 | -7.6 Million CAD | -73636.19% |
| 2015 FY | -12.01 Million CAD | -9081.83% |
| 2015 Q2 | -2.94 Million CAD | -103.53% |
| 2015 Q1 | -1.44 Million CAD | -2121.37% |
| 2015 Q3 | -10.32 Thousand CAD | 99.65% |
| 2014 Q2 | -29.97 Thousand CAD | -265.77% |
| 2014 Q1 | -8194.00 CAD | 61.25% |
| 2014 FY | -130.81 Thousand CAD | -70.13% |
| 2014 Q4 | -65.12 Thousand CAD | -136.61% |
| 2014 Q3 | -27.52 Thousand CAD | 8.17% |
| 2013 Q4 | -21.14 Thousand CAD | -23.89% |
| 2013 Q2 | -32.51 Thousand CAD | -139.93% |
| 2013 Q3 | -17.06 Thousand CAD | 47.5% |
| 2013 Q1 | -13.55 Thousand CAD | -412.93% |
| 2013 FY | -76.88 Thousand CAD | 13.51% |
| 2012 Q4 | 4330.00 CAD | 117.61% |
| 2012 FY | -88.89 Thousand CAD | 75.48% |
| 2012 Q1 | -35.52 Thousand CAD | -192.03% |
| 2012 Q2 | -33.11 Thousand CAD | 6.79% |
| 2012 Q3 | -24.58 Thousand CAD | 25.77% |
| 2011 Q1 | -177.57 Thousand CAD | -238.45% |
| 2011 Q3 | -154.36 Thousand CAD | -110.45% |
| 2011 Q4 | 38.6 Thousand CAD | 125.01% |
| 2011 FY | -362.51 Thousand CAD | -151.16% |
| 2011 Q2 | -73.35 Thousand CAD | 58.69% |
| 2010 Q2 | -42.52 Thousand CAD | -57.19% |
| 2010 Q1 | -27.05 Thousand CAD | -68.16% |
| 2010 Q4 | -52.46 Thousand CAD | -159.92% |
| 2010 FY | -144.33 Thousand CAD | -21.33% |
| 2010 Q3 | -20.18 Thousand CAD | 52.53% |
| 2009 Q2 | -75.96 Thousand CAD | -493.3% |
| 2009 Q3 | -14.11 Thousand CAD | 81.42% |
| 2009 FY | -118.96 Thousand CAD | 81.79% |
| 2009 Q4 | -16.08 Thousand CAD | -13.96% |
| 2009 Q1 | -12.8 Thousand CAD | 0.0% |
| 2008 FY | -653.23 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -5.01 Million CAD | 35.428% |
| Asep Medical Holdings Inc | -7.72 Million CAD | 58.035% |
| BioVaxys Technology Corp. | -2.4 Million CAD | -34.864% |
| ChitogenX Inc. | -2.83 Million CAD | -14.496% |
| Rapid Dose Therapeutics Corp. | -3.73 Million CAD | 13.334% |
| Defence Therapeutics Inc. | -12.65 Million CAD | 74.397% |
| Entheon Biomedical Corp. | -313.99 Thousand CAD | -931.95% |
| Gemina Laboratories Ltd. | -5.08 Million CAD | 36.29% |
| Glow Lifetech Corp. | -1.64 Million CAD | -97.25% |
| Lexston Life Sciences Corp. | -674.71 Thousand CAD | -380.236% |
| Pharmala Biotech Holdings Inc. | -762.95 Thousand CAD | -324.699% |
| Doseology Sciences Inc. | -377.63 Thousand CAD | -758.04% |
| MYND Life Sciences Inc. | -1.8 Million CAD | -79.239% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | -169.504% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | -6.444% |
| PreveCeutical Medical Inc. | -963.12 Thousand CAD | -236.43% |
| Telescope Innovations Corp. | -5.76 Million CAD | 43.812% |